|
gptkb:ImmTOR_platform
|
gptkb:SEL-302
|
|
gptkb:TransCon_hGH
|
Phase 3
|
|
gptkb:ArtemiC
|
Phase II
|
|
gptkb:CYP21A2_gene
|
yes
|
|
gptkb:KRT8_gene
|
immunohistochemistry for epithelial tumors
|
|
gptkb:oral_semaglutide_(Rybelsus)
|
PIONEER program
|
|
gptkb:intepirdine
|
Phase III (failed)
|
|
gptkb:Polo-like_kinase_1_(PLK1)
|
PLK1 inhibitors in cancer therapy
|
|
gptkb:COL1A1
|
yes
|
|
gptkb:17-DMAG
|
investigational
|
|
gptkb:ACE_gene
|
ACE I/D polymorphism genotyping
|
|
gptkb:Skycovione
|
Phase 3
|
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
|
Phase III
|
|
gptkb:lanabecestat
|
terminated
|
|
gptkb:NCT01449370
|
Phase 3
|
|
gptkb:Pfizer-BioNTech
|
July-November 2020
|
|
gptkb:BNT162b2_COVID-19_vaccine
|
July 2020 - November 2020
|
|
gptkb:hsa:6647
|
SOD2 polymorphism and disease risk
|
|
gptkb:Nkarta,_Inc.
|
NKX019 for B-cell malignancies
|
|
gptkb:Immunovant,_Inc.
|
warm autoimmune hemolytic anemia
|